Potential Risk of Cardiac Events in Patients Treated With Abacavir-Containing Products
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Potential Risk of Cardiac Events in Patients Treated With Abacavir-Containing Products

OTTAWA, Ontario -- June 25, 2008 -- New safety information regarding a potential increased risk of myocardial infarction in HIV-infected patients treated with abacavir-containing medicinal products (Ziagen, Kivexa, and Trizivir) has been released by Health Canada.

These recent findings were published in The Lancet. The new safety information is based on an ongoing prospective observational study, The Data Collection of Adverse Effects of Anti-HIV Drugs (D:A:D) study that was designed to quantify the incidence of myocardial infarction in HIV-infected patients receiving combination antiretroviral therapy. The D:A:D study, initiated in 1999, includes to date more than 33,000 HIV patients within 11 cohorts in Europe, United States, and Australia. Analyses of data collected up to February 1, 2007, suggest that there is a potential increased risk of myocardial infarction in HIV-infected patients treated with abacavir-containing medicinal products. This elevated risk does not appear to increase further over time, and no excess risk was present in patients who had stopped taking abacavir more than 6 months previously.

Health Canada has undertaken the review of these safety data and will advise Canadians if further risk measures are deemed necessary.

SOURCE: Health Canada

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities